REG - Oxford BioDynamics - Collaboration with Google Cloud

Oxford BiodynamicsAnnouncement

13/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250813:nRSM0516Va&default-theme=true

RNS Number : 0516V  Oxford BioDynamics PLC  13 August 2025

13 August 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

 

Oxford BioDynamics and Google Cloud Agree to Collaborate and Help Accelerate
Cloud-Based Analytical Frameworks for Precision Medicine

Oxford, UK - 13 August 2025 - Oxford BioDynamics (OBD), a biotechnology
company pioneering the use of 3D genomic biomarkers for clinical diagnostics,
is pleased to announce that it is collaborating with Google Cloud to support
the development and deployment of OBD's cutting-edge analytical framework on
the cloud.

Through this collaboration, Google Cloud will provide support via cloud
computing, enabling OBD to scale its proprietary EpiSwitch® knowledge space
and analytical tools and deliver high-throughput, AI-powered 3D genomic
analytics in a secure, efficient, and globally accessible environment to the
benefit of its pharma and biotech partners. This effort marks an important
milestone in OBD's digital transformation and utilisation of its knowledge
base and reflects Google Cloud's commitment to empowering innovative life
sciences research through its advanced cloud infrastructure.

Iain Ross, Executive Chairman of OBD said "Working with Google Cloud allows
OBD to rapidly scale its analytical capabilities, bringing it closer to
delivering precision 3D genomics insights in real time. Since joining the
company, I have been convinced of the value of our 3D Genomics knowledgebase
and the formation of this collaboration with Google Cloud only serves to
validate this view. We are excited to develop a powerful and interoperable
platform that aligns with the future of cloud-native biomedical research.
Google Cloud's global infrastructure allows us to share insights faster,
collaborate more easily with our partners, and bring our predictive genomic
tools into clinics and labs around the world - at scale."

Background

OBD's growth trajectory across translational research, diagnostic development,
and strategic partnerships is the key impetus for this collaboration with
Google Cloud. The allocated resources will support containerized deployment,
integration with Google Cloud's AI/ML tools, and secure, scalable data
processing pipelines that meet healthcare compliance standards which will make
the OBD platform more accessible to pharma and biotech companies and create
future opportunities to commercialise the EpiSwitch platform.

OBD will provide access to its EpiSwitch® platform, a clinically validated
technology that reveals regulatory 3D genome architecture changes, enabling
the detection of complex disease signatures, disease understanding and target
development.

OBD will work closely to monitor resource usage and performance benchmarks,
ensuring a scalable and cost-effective model for ongoing innovation.

For further information please contact:

 Oxford BioDynamics Plc                        +44 (0)1865 518910

 Iain Ross, Executive Chairman

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser and Broker  +44 (0)20 7408 4090

 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy

 Camarco - Financial PR

 Marc Cohen / Tilly Butcher / Fergus Young     +44 (0)20 3757 4980

                                               OBDFinancial@camarco.co.uk

About Oxford BioDynamics

Oxford BioDynamics Plc (AIM: OBD) is a biotechnology company focused on the
discovery and development of epigenetic biomarkers for use in clinical
diagnostics and precision medicine. Its proprietary EpiSwitch® platform
enables the detection of 3D genomic markers with wide applications in
immuno-oncology, neurodegeneration, and pharmacogenomics

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASPAFLNSEFA